![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: OLFML3 |
Gene summary for OLFML3 |
![]() |
Gene information | Species | Human | Gene symbol | OLFML3 | Gene ID | 56944 |
Gene name | olfactomedin like 3 | |
Gene Alias | HNOEL-iso | |
Cytomap | 1p13.2 | |
Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NRN5 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56944 | OLFML3 | AEH-subject1 | Human | Endometrium | AEH | 2.97e-36 | -6.14e-01 | -0.3059 |
56944 | OLFML3 | AEH-subject2 | Human | Endometrium | AEH | 3.35e-31 | -6.00e-01 | -0.2525 |
56944 | OLFML3 | AEH-subject3 | Human | Endometrium | AEH | 1.50e-18 | -4.71e-01 | -0.2576 |
56944 | OLFML3 | AEH-subject4 | Human | Endometrium | AEH | 5.81e-21 | -5.56e-01 | -0.2657 |
56944 | OLFML3 | AEH-subject5 | Human | Endometrium | AEH | 7.20e-37 | -6.19e-01 | -0.2953 |
56944 | OLFML3 | EEC-subject1 | Human | Endometrium | EEC | 6.85e-28 | -5.77e-01 | -0.2682 |
56944 | OLFML3 | EEC-subject2 | Human | Endometrium | EEC | 7.62e-40 | -6.21e-01 | -0.2607 |
56944 | OLFML3 | EEC-subject3 | Human | Endometrium | EEC | 3.56e-40 | -6.08e-01 | -0.2525 |
56944 | OLFML3 | EEC-subject4 | Human | Endometrium | EEC | 1.97e-27 | -5.72e-01 | -0.2571 |
56944 | OLFML3 | EEC-subject5 | Human | Endometrium | EEC | 3.93e-32 | -5.96e-01 | -0.249 |
56944 | OLFML3 | GSM5276934 | Human | Endometrium | EEC | 1.07e-05 | -3.20e-01 | -0.0913 |
56944 | OLFML3 | GSM5276935 | Human | Endometrium | EEC | 1.23e-35 | -6.18e-01 | -0.123 |
56944 | OLFML3 | GSM5276937 | Human | Endometrium | EEC | 6.88e-12 | -4.47e-01 | -0.0897 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib1_lib1 | Human | Endometrium | EEC | 2.51e-33 | -6.37e-01 | -0.1869 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib2_lib2 | Human | Endometrium | EEC | 7.55e-30 | -6.37e-01 | -0.1875 |
56944 | OLFML3 | GSM6177620_NYU_UCEC1_lib3_lib3 | Human | Endometrium | EEC | 1.14e-29 | -6.15e-01 | -0.1883 |
56944 | OLFML3 | GSM6177621_NYU_UCEC2_lib1_lib1 | Human | Endometrium | EEC | 1.38e-36 | -6.01e-01 | -0.1934 |
56944 | OLFML3 | GSM6177622_NYU_UCEC3_lib1_lib1 | Human | Endometrium | EEC | 1.36e-43 | -6.37e-01 | -0.1917 |
56944 | OLFML3 | GSM6177622_NYU_UCEC3_lib2_lib2 | Human | Endometrium | EEC | 5.68e-44 | -6.37e-01 | -0.1916 |
56944 | OLFML3 | GSM6177623_NYU_UCEC3_Vis | Human | Endometrium | EEC | 5.24e-13 | -4.78e-01 | -0.1269 |
Page: 1 2 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
OLFML3 | SNV | Missense_Mutation | rs775272671 | c.266G>A | p.Arg89His | p.R89H | Q9NRN5 | protein_coding | deleterious(0) | probably_damaging(0.912) | TCGA-AC-A3TM-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | CR |
OLFML3 | SNV | Missense_Mutation | novel | c.371G>T | p.Arg124Ile | p.R124I | Q9NRN5 | protein_coding | deleterious(0.01) | benign(0.011) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OLFML3 | SNV | Missense_Mutation | novel | c.1139G>A | p.Arg380Gln | p.R380Q | Q9NRN5 | protein_coding | tolerated(0.61) | possibly_damaging(0.475) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
OLFML3 | SNV | Missense_Mutation | c.183N>C | p.Lys61Asn | p.K61N | Q9NRN5 | protein_coding | tolerated(0.18) | benign(0.291) | TCGA-AO-A0J4-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
OLFML3 | SNV | Missense_Mutation | rs758802318 | c.721N>G | p.Leu241Val | p.L241V | Q9NRN5 | protein_coding | tolerated(1) | benign(0.007) | TCGA-BH-A0DK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
OLFML3 | SNV | Missense_Mutation | rs377336789 | c.587N>A | p.Arg196Gln | p.R196Q | Q9NRN5 | protein_coding | tolerated(0.54) | benign(0.392) | TCGA-BH-A0EE-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | docetaxel | SD |
OLFML3 | SNV | Missense_Mutation | novel | c.454N>T | p.Gly152Cys | p.G152C | Q9NRN5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A18U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
OLFML3 | insertion | Nonsense_Mutation | novel | c.310_311insCCAGCTTCTACTGAACAAGGCTGAAAACCCACTCTAT | p.Leu104ProfsTer5 | p.L104Pfs*5 | Q9NRN5 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
OLFML3 | SNV | Missense_Mutation | c.69N>C | p.Gln23His | p.Q23H | Q9NRN5 | protein_coding | tolerated(0.27) | benign(0.007) | TCGA-AA-3492-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
OLFML3 | SNV | Missense_Mutation | rs376475211 | c.449G>A | p.Arg150Gln | p.R150Q | Q9NRN5 | protein_coding | deleterious(0.01) | probably_damaging(0.941) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |